262 related articles for article (PubMed ID: 37375331)
1. Morin Hydrate Encapsulation and Release from Mesoporous Silica Nanoparticles for Melanoma Therapy.
Cunha C; Marinheiro D; Ferreira BJML; Oliveira H; Daniel-da-Silva AL
Molecules; 2023 Jun; 28(12):. PubMed ID: 37375331
[TBL] [Abstract][Full Text] [Related]
2. Encapsulation and Enhanced Release of Resveratrol from Mesoporous Silica Nanoparticles for Melanoma Therapy.
Marinheiro D; Ferreira BJML; Oskoei P; Oliveira H; Daniel-da-Silva AL
Materials (Basel); 2021 Mar; 14(6):. PubMed ID: 33809119
[TBL] [Abstract][Full Text] [Related]
3. Facile Synthesis of Three Types of Mesoporous Silica Microspheres as Drug Delivery Carriers and their Sustained-Release Properties.
Zhu Y; Wang B; Chen J; He J; Qiu X
Curr Drug Deliv; 2023; 20(9):1337-1350. PubMed ID: 35713141
[TBL] [Abstract][Full Text] [Related]
4. Novel scheme for rapid synthesis of hollow mesoporous silica nanoparticles (HMSNs) and their application as an efficient delivery carrier for oral bioavailability improvement of poorly water-soluble BCS type II drugs.
Li T; Geng T; Md A; Banerjee P; Wang B
Colloids Surf B Biointerfaces; 2019 Apr; 176():185-193. PubMed ID: 30616109
[TBL] [Abstract][Full Text] [Related]
5. Carboxyl-functionalized mesoporous silica nanoparticles for the controlled delivery of poorly water-soluble non-steroidal anti-inflammatory drugs.
Gou K; Wang Y; Guo X; Wang Y; Bian Y; Zhao H; Guo Y; Pang Y; Xie L; Li S; Li H
Acta Biomater; 2021 Oct; 134():576-592. PubMed ID: 34280558
[TBL] [Abstract][Full Text] [Related]
6. Morin hydrate loaded solid lipid nanoparticles: Characterization, stability, anticancer activity, and bioavailability.
Karamchedu S; Tunki L; Kulhari H; Pooja D
Chem Phys Lipids; 2020 Nov; 233():104988. PubMed ID: 33035545
[TBL] [Abstract][Full Text] [Related]
7. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
[TBL] [Abstract][Full Text] [Related]
8. Polyaspartic acid-anchored mesoporous silica nanoparticles for pH-responsive doxorubicin release.
Hakeem A; Zahid F; Zhan G; Yi P; Yang H; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1029-1040. PubMed ID: 29497295
[TBL] [Abstract][Full Text] [Related]
9. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia.
Heydari SR; Ghahremani MH; Atyabi F; Bafkary R; Jaafari MR; Dinarvand R
Int J Pharm; 2023 Nov; 646():123495. PubMed ID: 37806507
[TBL] [Abstract][Full Text] [Related]
10. Improving Solubility and Bioavailability of Breviscapine with Mesoporous Silica Nanoparticles Prepared Using Ultrasound-Assisted Solution-Enhanced Dispersion by Supercritical Fluids Method.
Yang G; Li Z; Wu F; Chen M; Wang R; Zhu H; Li Q; Yuan Y
Int J Nanomedicine; 2020; 15():1661-1675. PubMed ID: 32210559
[TBL] [Abstract][Full Text] [Related]
11. Egg-yolk core-shell mesoporous silica nanoparticles for high doxorubicin loading and delivery to prostate cancer cells.
Tiburcius S; Krishnan K; Jose L; Patel V; Ghosh A; Sathish CI; Weidenhofer J; Yang JH; Verrills NM; Karakoti A; Vinu A
Nanoscale; 2022 May; 14(18):6830-6845. PubMed ID: 35441642
[TBL] [Abstract][Full Text] [Related]
12. Modified mesoporous silica nanoparticles for enhancing oral bioavailability and antihypertensive activity of poorly water soluble valsartan.
Biswas N
Eur J Pharm Sci; 2017 Mar; 99():152-160. PubMed ID: 27993684
[TBL] [Abstract][Full Text] [Related]
13. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
Gupta A; Kushwaha SS; Mishra A
Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
[TBL] [Abstract][Full Text] [Related]
14. Functionalized Mesoporous Silica Nanoparticles for Drug-Delivery to Multidrug-Resistant Cancer Cells.
Igaz N; Bélteky P; Kovács D; Papp C; Rónavári A; Szabó D; Gácser A; Kónya Z; Kiricsi M
Int J Nanomedicine; 2022; 17():3079-3096. PubMed ID: 35859731
[TBL] [Abstract][Full Text] [Related]
15. Dual response to pH and chiral microenvironments for the release of a flurbiprofen-loaded chiral self-assembled mesoporous silica drug delivery system.
Wu L; Gou K; Guo X; Guo Y; Chen M; Hou J; Li S; Li H
Colloids Surf B Biointerfaces; 2021 Mar; 199():111501. PubMed ID: 33338882
[TBL] [Abstract][Full Text] [Related]
16. Thermo-responsive mesoporous silica/lipid bilayer hybrid nanoparticles for doxorubicin on-demand delivery and reduced premature release.
Zhang Q; Chen X; Shi H; Dong G; Zhou M; Wang T; Xin H
Colloids Surf B Biointerfaces; 2017 Dec; 160():527-534. PubMed ID: 29024917
[TBL] [Abstract][Full Text] [Related]
17. Polydopamine-based surface modification of mesoporous silica nanoparticles as pH-sensitive drug delivery vehicles for cancer therapy.
Chang D; Gao Y; Wang L; Liu G; Chen Y; Wang T; Tao W; Mei L; Huang L; Zeng X
J Colloid Interface Sci; 2016 Feb; 463():279-87. PubMed ID: 26550786
[TBL] [Abstract][Full Text] [Related]
18. Preparation, in vitro and in vivo evaluation of polymeric nanoparticles based on hyaluronic acid-poly(butyl cyanoacrylate) and D-alpha-tocopheryl polyethylene glycol 1000 succinate for tumor-targeted delivery of morin hydrate.
Abbad S; Wang C; Waddad AY; Lv H; Zhou J
Int J Nanomedicine; 2015; 10():305-20. PubMed ID: 25609946
[TBL] [Abstract][Full Text] [Related]
19. Chitosan-capped mesoporous silica nanoparticles as pH-responsive nanocarriers for controlled drug release.
Hu X; Wang Y; Peng B
Chem Asian J; 2014 Jan; 9(1):319-27. PubMed ID: 24115568
[TBL] [Abstract][Full Text] [Related]
20. Co-Delivery of Silymarin and Metformin Dual-Loaded in Mesoporous Silica Nanoparticles Synergistically Sensitizes Breast Cancer Cell Line to Mitoxantrone Chemotherapy.
Rezaei Harandi Z; Heidari R; Reiisi S
IEEE Trans Nanobioscience; 2023 Oct; 22(4):872-880. PubMed ID: 37022888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
